Table 3. Eligibility and treatment of chronic hepatitis B cases with reported treatment status by country, hepatitis pilot sentinel surveillance system, Croatia, Romania, Spain, January–June 2019.
| Reported treatment status | Croatia | Romania | Spain | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Number of cases (total n = 24) | % | Number of cases (total n = 150) | % | Number of cases (total n = 55) | % | Number of cases (total n = 203) | % | |
| Eligible for treatment | 24 | 100 | 46 | 31 | 10 | 18 | 80 | 39 |
| Eligibility treatment criteria | 24 | NA | 46 | NA | 10 | NA | 80 | NA |
| EASL | 18 | 75 | 24 | 52 | 10 | 100 | 52 | 73 |
| Local | 6 | 25 | 22 | 48 | 0 | 0 | 28 | 27 |
| Reported treatment status | 24 | NA | 46 | NA | 10 | NA | 80 | NA |
| Treated | 23 | 96 | 12 | 26 | 6 | 60 | 41 | 51 |
| Treatment regimen | 22 | NA | 12 | NA | 6 | NA | 40 | NA |
| Lamivudine | 7 | 32 | 12 | 100 | 0 | 0 | 19 | 48 |
| Tenofovir | 12 | 55 | 0 | 0 | 6 | 100 | 18 | 45 |
| Other/multiple regimens | 3 | 14 | 0 | 0 | 0 | 0 | 3 | 8 |
| Viral suppression | 23 | NA | 11 | NA | 3 | NA | 37 | NA |
| Yes | 20 | 87 | 11 | 100 | 2 | 67 | 33 | 89 |
| Diagnosis to treatment start | 17 | NA | 12 | NA | 4 | NA | 33 | NA |
| Median days (IQR) | 1,375 (94–3,495) |
75 (7–189) |
278 (187–301) |
188 (87–1,375) |
||||
| Attendance to treatment start | 22 | NA | 12 | NA | 6 | NA | 40 | NA |
| Median days (IQR) | 51 (0–92) |
188 (48–192) |
151 (14–259) |
75 (18–189) |
||||
EASL: European Association for the Study of the Liver; IQR: interquartile range; NA: not applicable.
Of the 229 participants in the study, treatment status was available for 203.
Numbers in bold indicate total cases with complete information for each variable.